TRCT
BCAB icon

Tower Research Capital (TRC)’s BioAtla BCAB Stock Holding History

Tower Research Capital (TRC)’s Portfolio BCAB Stock Details BCAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.74K Buy
340
+234
+221% +$2.74K ﹤0.01% 4424
2025
Q4 		$3.02K Buy
+106
New +$4.16K ﹤0.01% 4434
2025
Q3 		– Sell
-466
Closed -$9.23K – 5225
2025
Q2 		$9.23K Buy
+466
New +$9.45K ﹤0.01% 3996
2025
Q1 		– Sell
-119
Closed -$3.51K – 5195
2024
Q4 		$3.51K Buy
119
+16
+16% +$1.34K ﹤0.01% 4646
2024
Q3 		$9.04K Sell
103
-254
-71% -$21.3K ﹤0.01% 3912
2024
Q2 		$24.5K Buy
357
+327
+1,090% +$38.9K ﹤0.01% 3641
2024
Q1 		$5.16K Sell
30
-68
-69% -$8.45K ﹤0.01% 4579
2023
Q4 		$12.1K Sell
98
-56
-36% -$4.86K ﹤0.01% 4075
2023
Q3 		$13.1K Buy
154
+61
+66% +$7.78K ﹤0.01% 3828
2023
Q2 		$13.9K Sell
93
-133
-59% -$22.9K ﹤0.01% 3731
2023
Q1 		$30K Buy
226
+94
+71% +$16.9K ﹤0.01% 2983
2022
Q4 		$54K Buy
132
+92
+230% +$38.2K ﹤0.01% 2286
2022
Q3 		$15K Sell
40
-62
-61% -$20.3K ﹤0.01% 4154
2022
Q2 		$14K Sell
102
-49
-32% -$7.8K ﹤0.01% 4127
2022
Q1 		$37K Buy
151
+65
+76% +$27.2K ﹤0.01% 2955
2021
Q4 		$84K Buy
86
+30
+54% +$38.4K ﹤0.01% 2346
2021
Q3 		$83K Buy
56
+46
+460% +$89.6K ﹤0.01% 2544
2021
Q2 		$20K Sell
10
-20
-67% -$45.2K ﹤0.01% 3871
2021
Q1 		$76K Buy
+30
New +$76.9K ﹤0.01% 2792

Other funds holding BCAB

ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Tower Research Capital (TRC)'s BCAB Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its BioAtla (BCAB) stake by 221% in Q1 2026, buying an estimated $2.74K and bringing the position to 340 shares worth $2.74K. The position accounts for ﹤0.01% of the portfolio, ranked #4424.

Tower Research Capital (TRC) first reported a position in BCAB in Q1 2021 and has held it in 19 quarters since. The position peaked at $84K in Q4 2021. 36 funds tracked by Wall St. Rank hold BCAB as of Q1 2026.

  • Tower Research Capital (TRC) held 340 shares of BioAtla worth $2.74K as of Q1 2026.
  • Tower Research Capital (TRC) bought 234 BioAtla shares in Q1 2026, an estimated $2.74K.
  • BioAtla made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4424 holding.
  • Tower Research Capital (TRC) first reported a position in BioAtla in Q1 2021 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s BioAtla position peaked at $84K in Q4 2021.
  • 36 funds tracked by Wall St. Rank held BioAtla as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.